Physician profile
Katrina Wright
NPI 1073501136
$1,581.26
in general payments reported to CMS, 2019-2025
13 companies · $654 in 2025
The $654 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $49.17 · 2021: $41.73 · 2022: $27.16 · 2023: $416 · 2024: $281 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,313 · Education: $36.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,313.24 |
| Education | $36.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $382.54 | 2021-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $323.72 | 2022-2025 | Velphoro, Velphoro, Korsuva |
| Otsuka America Pharmaceutical, INC. | $203.70 | 2019-2025 | Jynarque |
| Amgen INC. | $123.55 | 2020-2025 | Krystexxa, Tavneos |
| Opko Pharmaceuticals, LLC | $106.14 | 2023-2025 | Rayaldee |
| Ekos Corporation | $93.33 | 2019 | |
| Novo Nordisk INC | $89.18 | 2023-2025 | Ozempic |
| Ardelyx, INC. | $75.02 | 2025 | Ibsrela |
| Astellas Pharma US INC | $66.23 | 2025 | Veozah |
| Lilly USA, LLC | $49.79 | 2025 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $24.72 | 2020 | |
| Vifor Pharma, INC. | $23.23 | 2021 | |
| Calliditas Therapeutics US INC. | $20.11 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.